301 related articles for article (PubMed ID: 18191005)
1. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.
Blaney JE; Sathe NS; Goddard L; Hanson CT; Romero TA; Hanley KA; Murphy BR; Whitehead SS
Vaccine; 2008 Feb; 26(6):817-28. PubMed ID: 18191005
[TBL] [Abstract][Full Text] [Related]
2. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
[TBL] [Abstract][Full Text] [Related]
3. Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
Blaney JE; Hanson CT; Firestone CY; Hanley KA; Murphy BR; Whitehead SS
Am J Trop Med Hyg; 2004 Dec; 71(6):811-21. PubMed ID: 15642976
[TBL] [Abstract][Full Text] [Related]
4. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
Hanley KA; Manlucu LR; Manipon GG; Hanson CT; Whitehead SS; Murphy BR; Blaney JE
Vaccine; 2004 Sep; 22(25-26):3440-8. PubMed ID: 15308370
[TBL] [Abstract][Full Text] [Related]
5. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Blaney JE; Matro JM; Murphy BR; Whitehead SS
J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
[TBL] [Abstract][Full Text] [Related]
6. A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.
Li XF; Deng YQ; Yang HQ; Zhao H; Jiang T; Yu XD; Li SH; Ye Q; Zhu SY; Wang HJ; Zhang Y; Ma J; Yu YX; Liu ZY; Li YH; Qin ED; Shi PY; Qin CF
J Virol; 2013 Dec; 87(24):13694-705. PubMed ID: 24109223
[TBL] [Abstract][Full Text] [Related]
7. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys.
Whitehead SS; Falgout B; Hanley KA; Blaney JE; Markoff L; Murphy BR
J Virol; 2003 Jan; 77(2):1653-7. PubMed ID: 12502885
[TBL] [Abstract][Full Text] [Related]
8. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
[TBL] [Abstract][Full Text] [Related]
9. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
[TBL] [Abstract][Full Text] [Related]
10. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
11. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
[TBL] [Abstract][Full Text] [Related]
12. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
[TBL] [Abstract][Full Text] [Related]
13. Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeys.
Lin HH; Lee HC; Li XF; Tsai MJ; Hsiao HJ; Peng JG; Sue SC; Qin CF; Wu SC
PLoS One; 2014; 9(6):e100130. PubMed ID: 24959738
[TBL] [Abstract][Full Text] [Related]
14. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
[TBL] [Abstract][Full Text] [Related]
15. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
16. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
[TBL] [Abstract][Full Text] [Related]
17. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys.
Men R; Bray M; Clark D; Chanock RM; Lai CJ
J Virol; 1996 Jun; 70(6):3930-7. PubMed ID: 8648730
[TBL] [Abstract][Full Text] [Related]
18. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
19. Extensive genomic recoding by codon-pair deoptimization selective for mammals is a flexible tool to generate attenuated vaccine candidates for dengue virus 2.
Stauft CB; Song Y; Gorbatsevych O; Pantoja P; Rodriguez IV; Futcher B; Sariol CA; Wimmer E
Virology; 2019 Nov; 537():237-245. PubMed ID: 31539771
[TBL] [Abstract][Full Text] [Related]
20. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
Whitehead SS; Hanley KA; Blaney JE; Gilmore LE; Elkins WR; Murphy BR
Vaccine; 2003 Oct; 21(27-30):4307-16. PubMed ID: 14505913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
